Pathogenesis of idiopathic nephrotic syndrome in children: molecular mechanisms and therapeutic implications

Samuel N Uwaezuoke

Pediatric Nephrology Firm, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria

Abstract

The conventional paradigm on the pathogenesis of nephrotic syndrome revolves around the concept of a glomerular disorder which is characterized by massive proteinuria with consequent hypoalbuminemia, generalized edema and hyperlipidemia. However, the changes at structural and molecular levels of the podocytes have recently assumed prominence as a new paradigm on the pathogenesis of pediatric idiopathic nephrotic syndrome. A number of complex molecular pathways with inter-related nexus result in a molecular disorientation of the slit diaphragm or the glomerular basement membrane leading to proteinuria, as well as in a rearrangement of the podocyte cytoskeleton which is responsible for foot process effacement. In acquired podocytodopathies such as focal segmental glomerulosclerosis and minimal change disease, the molecular changes observed in proteins from the cytoskeleton, cell transmembrane, and the slit diaphragm induce foot process effacement and change disease, the molecular changes observed in proteins from the cytoskeleton, cell transmembrane, and the slit diaphragm induce foot process effacement and changes in negative charges which eventuates in massive proteinuria. Development of drugs able to affect these molecular pathways that regulate podocyte injury offers hope for targeted and effective treatments for nephrotic syndrome in future. Moreover, the causal association between multiple genetic mutations and the changes at structural and molecular levels of the podocytes have recently assumed prominence as a new paradigm on the pathogenesis of pediatric idiopathic nephrotic syndrome. A number of complex molecular pathways with inter-related nexus result in a molecular disorientation of the slit diaphragm or the glomerular basement membrane leading to proteinuria, as well as in a rearrangement responsible for foot process effacement; and renal avidity for sodium and edema formation resulting from a primary stimulation of tubular sodium, K⁺-ATPase and an increase of endothelial permeability [7].

This review will discuss the recent hypothesized molecular mechanisms involved in the pathogenesis of idiopathic nephrotic syndrome (the podocytodopathies), and the therapeutic implications.

Introduction

The conventional paradigm on the pathogenesis of nephrotic syndrome revolves around the concept of a glomerular disorder which is characterized by massive proteinuria. The podocytopathies are characterized by changes in the podocytes, which may be at the structural or molecular levels. The changes at the molecular levels have recently assumed prominence as a new paradigm on the pathogenesis of idiopathic nephrotic syndrome in children. In addition, emerging data suggest that steroid-sensitive nephrotic syndrome, as well as a subset of steroid-resistant nephrotic syndrome (particularly those recurring after transplantation) have an immunological basis. For instance, it appears that T cells in these patients promote the production of a circulating factor, which alters the permeability of the glomerular filtration barrier.

Many vascular permeability factors have been postulated, and these include vascular endothelial growth factor, heparanase, hemopexin and soluble urokinase receptor (suPAR) [4,5]. In addition, podocytes have been found to express receptors for type 2 cytokines (interleukin-4 and interleukin-13) elaborated by T cells, which if activated may also disrupt glomerular permeability leading to proteinuria [6]. In a nutshell, idiopathic nephrotic syndrome has been defined as a T-cell disorder associated with a functional renal impairment in which the molecular mechanisms leading from the stimulation of the immune system to the clinical expression of the renal disease can be analyzed according to five biological events: a Th2 activation of T cells by interleukin-13; a yet unresolved glomerular permeability factor of immune origin; a molecular disorientation of slit diaphragms or glomerular basement membrane responsible for proteinuria; a podocyte cytoskeleton rearrangement responsible for foot process effacement; and renal avidity for sodium and edema formation resulting from a primary stimulation of tubular sodium, K⁺-ATPase and an increase of endothelial permeability [7].

This review will discuss the recent hypothesized molecular mechanisms involved in the pathogenesis of idiopathic nephrotic syndrome (the podocytodopathies), and the therapeutic implications.

Podocytodopathies: The molecular basis

The podocyte contributes in maintaining the structural integrity of the glomerular filtration barrier as its injury and loss results in...
proteinuria and progressive sclerosis [8]. At the molecular level, focal adhesion kinase (FAK) is prominently involved in the effacement of the foot processes commonly seen in podocytopathies [9,10]. Changes in podocyte proteins such as nephrin and nephrin homologue- Nep1 [11], CD2-associated protein (CD2AP) [12,13] and podocin [14], all play an important role in the pathogenesis of podocytopathies. Nephrin is a vital component of the slit diaphragm and also functions as an effective recruiter of other proteins such as podocin and CD2AP [15]. Some authors suggest the existence of an important interaction between actin cytoskeleton structure and these components of the slit diaphragm namely podocin, nephrin and CD2AP [16,17]. Thus, in the nephrotic syndromes, there are changes in the podocytes which manifest as effacement of the podocyte foot processes, as well as structural alterations in the cytoskeleton and molecular reorganization of the slit diaphragm [18]. The molecular composition of the actin cytoskeleton (the skeletal structure of the foot processes) consists of actin, α-actinin, and synaptopodin [19,20]. Notably, the up-regulation of α-actinin is accompanied by cytoskeleton reorganization in some nephrotic syndromes [21], while the expression of synaptopodin is generally preserved in minimal change disease, but reduced in focal segmental glomerulosclerosis [22]. Podocalyxin is a molecule thought to be responsible for the stability of the foot processes [21,23], and is shown to be increased in nephrotic syndromes [24]. Another molecular component of the podocyte membrane is GLEPP-1 (a trans-membrane tyrosine-phosphatase) which might function as a receptor [25] or regulate both blood pressure and glomerular filtration rates [26]. The expression of GLEPP-1 appears to be down-regulated in focal segmental glomerulosclerosis but assumes normal levels in minimal change disease [27]. Furthermore, the expression of other podocyte cytoskeleton-bound proteins, such as the dystroglycans, is not altered in focal segmental glomerulosclerosis, but is decreased in active minimal change disease [28]. Yet another trans-membrane protein which might be directly involved in the pathogenesis of idiopathic nephrotic syndrome is the B7-1 molecule (CD80); it is commonly located only in the cell surface of B lymphocytes and antigen-presenting cells [29,30]. Some investigators have demonstrated that under stress B7-1 might be expressed on podocytes, which may cause reorganization of actin cytoskeleton and modulation of the molecular components of the slit diaphragm [31]. Again, the roles of elevated glomerular profibrotic cytokines such as interleukin-13 and interleukin-4 and elevated TGF-β levels in the pathogenesis of glomerular sclerosis seen in focal segmental glomerulosclerosis have been documented [32-36]. The TGF-β signaling pathway may act as a key mediator in cellular mechanisms responsible for glomerulosclerosis and interstitial fibrosis [37]. Elevated TGF-β1 production might induce the expression of integrin-linked kinase (ILK), a protein which is related to the pathogenesis of many nephropathies associated with proteinuria. The upregulation of ILK in the podocytes may determine the occurrence of epithelial-mesenchymal transition (EMT) in these cells [38]; these changes may lead to damage in glomerular filtration barrier resulting in proteinuria [39–41].

Finally, the role of Angiopoietin-like 4 (AngPl4) as mediator of persistent proteinuria and hyperlipidemia in minimal change disease remains an interesting update as the molecule holds prospects for novel therapeutic interventions in nephrotic syndrome [42]. In the circulation, a normosialylated form of AngPl4 binds to glomerular endothelial αvβ3 integrin to reduce proteinuria, or inactivates endothelium-bound lipoprotein lipase to reduce the hydrolysis of plasma triglycerides to free fatty acids resulting in hyperlipidemia [43]. Conversely, podocytes in minimal change disease produce a hyposialylated form of AngPl4 which remains confined to the kidney and induces proteinuria [44].

**Therapeutic implications of the new paradigm on pathogenesis**

Acquired podocytopathies (focal segmental glomerulosclerosis and minimal change disease) are considered as immunological diseases. Although the data on direct effects of immunosuppressive agents on proteinuria induced by podocyte dysfunction remain controversial, medications like glucocorticoids and calcineurin inhibitors have been noted to exert direct effects on podocytes through regulation of the cytokines( interleukin-4 and interleukin-13) and several signaling pathways responsible for stabilizing the actin cytoskeleton, cell maturation and survival, as well as the expression and distribution of key components of the slit diaphragm [8]. The therapeutic effectiveness of steroids in minimal change disease and calcineurin inhibitors in focal segmental glomerulosclerosis is well established; the non-immunological actions of calcineurin inhibitors actually include effects on the podocyte cytoskeleton and podocyte survival [8]. Better still, development of drugs which can affect the molecular pathways responsible for regulation of podocyte injury offers hope for targeted and effective treatments for nephrotic syndrome in future [45].

Secondly, the new knowledge about the existence of multiple mutations of the podocyte proteins which can cause nephrotic syndrome [46–48], has led to a more functionally applicable classification of the causes of the syndrome into ‘podocytopathies’ for mutations directly affecting podocyte structure or function, or ‘channelopathies’ for mutations affecting an ion channel such as the gene- TRPC6 [49]. A major treatment challenge in childhood nephrotic syndrome is that it is clearly not a single-disease entity more so with the multiple genetic mutations causally associated with it; examples of affected genes include NPHS 1, NPHS 2, CD2AP, PLCE 1, LAMB 2, ACTN 4, TRPC 6, INF 2 and ARH GAP 24 [48-52]. In future, this new concept on the grouping of the causes of nephrotic syndrome may translate into new therapeutic approaches in its treatment. Finally, another molecular mechanism with therapeutic implication is the pro-proteinuric action of podocyte-producing hyposialylated AngPl4; the mutant form of this protein molecule has the therapeutic potential as an anti-proteinuric agent [43,44].

**Conclusions**

The molecular mechanisms involved in the pathogenesis of idiopathic nephrotic syndrome are complex and depend on all the components of the glomerular filtration barrier. The plethora of podocyte molecules which form part of this trilaminate barrier and their identified gene mutations has opened up a new understanding on the non-syndromic causes of nephrotic syndrome. The podocyte which contributes in maintaining the structural integrity of the glomerular filtration barrier is composed of several distinct proteins; the changes in these proteins play an important role in the pathogenesis of focal segmental glomerulosclerosis and minimal change disease which constitute the acquired podocytopathies. Specifically, the molecular changes observed in proteins from the cytoskeleton, cell transmembrane, and slit diaphragm induce foot process effacement and changes in negative charges resulting in massive proteinuria seen in these podocytopathies. The new knowledge about these molecular mechanisms has established the role of immunosuppressive drugs on podocytopathies and holds prospects for novel treatment approaches.
References

angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med 20: 37-46. [Crossref]


50. Pei Y (2011) INF2 is another piece of the jigsaw puzzle for FSGS. J Am Soc Nephrol 22: 197-199. [Crossref]


Copyright: ©2015 Uwaezuoke SN. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.